Today: 2 December 2025
Subscribe
Browse Category

Healthcare News 21 October 2025 - 15 November 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the
15 November 2025
 ·  ·  ·  ·  · 
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY)
14 November 2025
 ·  ·  ·  ·  ·  · 
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial
13 November 2025
 ·  ·  ·  ·  · 
Scott Bessent Faces Fresh Scrutiny Over Medicare‑Tax ‘Limited Partner’ Loophole and an Unkept Back‑Taxes Pledge — What’s New on Nov. 12, 2025

Scott Bessent Faces Fresh Scrutiny Over Medicare‑Tax ‘Limited Partner’ Loophole and an Unkept Back‑Taxes Pledge — What’s New on Nov. 12, 2025

Treasury Secretary Scott Bessent is back under the microscope over his past use of a Medicare self‑employment tax loophole commonly claimed by hedge‑fund managers and other partnership owners. Senate Democrats have alleged since January that Bessent avoided roughly $900,000 in
12 November 2025
 ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and
6 November 2025
 ·  ·  ·  ·  ·  · 
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases gurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now
3 November 2025
 ·  ·  ·  ·  · 
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to
21 October 2025
 ·  ·  ·  ·  · 
1 2 3 4
Go toTop